NICOX SA (COX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:COX - FR0013018124 - Common Stock
COX.PA Key Statistics, Chart & Performance
The current stock price of COX.PA is 0.579 EUR. In the past month the price decreased by -8.1%. In the past year, price decreased by -66.14%.
COX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.35 | 48.75B | ||
| ARGX.BR | ARGENX SE | 73.61 | 48.26B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.97B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.22B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.25B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.80B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.06 | 991.20M | ||
| NANO.PA | NANOBIOTIX | N/A | 889.09M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 666.65M | ||
| 6IV.DE | INVENTIVA SA | N/A | 672.38M |
Related stock screener links
About COX.PA
Company Profile
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Info
NICOX SA
Drakkar 2 - Batiment D, 2405 route des Dolines, CS 10313 Sophia Antipolis
Valbonne PACA FR
Employees: 32
Phone: 33497245300.0
NICOX SA / COX.PA FAQ
What does NICOX SA do?
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Can you provide the latest stock price for NICOX SA?
The current stock price of COX.PA is 0.579 EUR. The price decreased by -0.52% in the last trading session.
Does NICOX SA pay dividends?
COX.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of COX stock?
COX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for COX stock?
The Revenue of NICOX SA (COX.PA) is expected to grow by 16.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
COX.PA Technical Analysis
COX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COX.PA. Both the profitability and financial health of COX.PA have multiple concerns.
COX.PA Financial Highlights
Over the last trailing twelve months COX.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 47.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.47 |
COX.PA Forecast & Estimates
8 analysts have analysed COX.PA and the average price target is 2.91 EUR. This implies a price increase of 402.07% is expected in the next year compared to the current price of 0.579.
For the next year, analysts expect an EPS growth of 35.92% and a revenue growth 16.23% for COX.PA